Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOVEDH)

Drug Name
SYM-004 Drug Info
Synonyms Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
Indication
Disease Entry ICD 11 Status REF
Metastatic colorectal cancer 2B91 Phase 3 [1]
Colorectal cancer 2B91.Z Phase 2 [2]
Head and neck cancer 2D42 Phase 2 [3]
Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Recurrent glioblastoma 2A00.00 Phase 2 [2] , [1] , [4]
Cross-matching ID
TTD Drug ID
DMOVEDH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Not Available [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Epidermal growth factor receptor (EGFR) DTT EGFR 6.045 4.991 5.317 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Metastatic colorectal cancer
ICD Disease Classification 2B91
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 1.04E-65 -0.89 -1.53
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02083653) Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.